Qinlock
Chemical Name | ripretinib |
Dosage Form | Tablet (oral; 50 mg) |
Drug Class | Kinase inhibitors |
System | Multiple |
Company | Deciphera Pharmaceuticals |
Approval Year | 2020 |
Indication
- For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.